March 5, 2014 | Israeli drug development company BiolineRX is planning a secondary offering on Nasdaq, in an attempt to raise $21 million. The company will use the proceeds for a Phase II clinical trial of its leukemia treatment and a Phase I clinical trial of its celiac disease treatment.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments